bisbenzimidazole trihydrochloride and Neoplasms

bisbenzimidazole trihydrochloride has been researched along with Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, C; Du, J; Fang, H; Hou, X; Li, X; Liu, M; Yang, X; Zhang, J; Zhao, H	1

Other Studies

1 other study(ies) available for bisbenzimidazole trihydrochloride and Neoplasms

Article	Year
Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; DNA; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Macrophages; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Docking Simulation; Neoplasms; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays	2022

Article

Year

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.

Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4

Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; DNA; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Macrophages; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Docking Simulation; Neoplasms; T-Lymphocytes; Tumor Microenvironment; Xenograft Model Antitumor Assays

2022